% 0期刊文章% Jiraporn Jitprapaikulsan %约翰·陈% Brian Weinshenker詹姆斯·弗莱尔% %一个万带兰列侬安德鲁·麦肯% %一个Eoin P·弗拉纳根杰奎琳·莱维特% %一个w·奥利弗·托宾% A·塞巴斯蒂安·洛佩兹奇% b .克劳迪娅Lucchinetti马克Keegan % % Orhun Kantarci %一个肖恩Pittock杰西卡请% % T梅奥诊所的神经胶质自身免疫研究:AQP4 / MOG-IgG serostatus和结果在228例患者出现复发性视神经炎(S13.007) % D J神经病学2018% % P S13.007 % V 90% N 15补充% X目的:确定aquaporin-4 (AQP4)和髓少突细胞糖蛋白(MOG)免疫球蛋白serostatus和视觉结果复发患者视神经炎(罗恩)。首页背景:AQP4-IgG和MOG-IgG是自身免疫性单相和罗恩的生物标志物。血清学可能预测视觉效果和复发的倾向。设计/方法:梅奥诊所的病人发现2000 - 2017年间,面对2攻击,储存血清。AQP4-IgG和MOG-IgG1 serostatus由验证流式细胞术分析决定利用M1-AQP4-transfected和全长MOG-transfected住HEK293细胞。结果:228名患者中有罗恩,仅179年罗恩(罗恩)和49罗恩与序贯其他炎性脱髓鞘攻击(rON +)。Serostatus罗恩队列:16 (9%)AQP4-IgG + 25 (14%) MOG-IgG1 + (4 CRION), 26(14%)多发性硬化症(MS)、112年(63%)双重否定/特发性(DN)。Serostatus罗恩+队列:15 (31%)AQP4-IgG + 4 (8%) MOG-IgG1 +, 19(39%)和11(22%)女士DN。罗恩的年复发率是MOG-IgG1 + 1.2, 0.67为DN, AQP4-IgG + 0.64, 0.43女士(MOG-IgG1 + vs女士(p = 0.009),其他比较没有统计学意义或p > 0.05)。平均视力(VA)最后跟进AQP4-IgG +受影响的眼睛是20/400,20/100 DN, 20/50为女士和20/40 MOG-IgG1 +组(p < 0.001)。中位数时间从发病到严重视力丧失(VA≥20/200) AQP4-IgG + 72个月,263女士,DN 364个月(p < 0.001)。只有3 29 MOG-IgG1 +集团发展严重的视力丧失。 Cumulative probabilities to develop severe vision loss at 5 years was 48% in AQP4-IgG+, 21% in DN, 8% in MS and MOG-IgG1+ groups (p<0.001).Conclusions: Most patients with recurrent ON lack a definitive biomarker. AQP4-IgG positive patients have worse visual outcome compared with MOG-IgG1+, MS, and double negative cases. MOG-IgG+ patients have highest relapse rate, but better visual outcome.Disclosure: Dr. Jitprapaikulsan has nothing to disclose. Dr. Chen has nothing to disclose. Dr. Fryer has nothing to disclose. Dr. Weinshenker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Alexion, MedImmune, Caladrius Biosciences, Brainstorm Therapeutics. Dr. McKeon has received research support from Medimmune, Euroimmun, Grifols and Alexion. Dr. Lennon has received royalty, license fees, or contractual rights payments from RSR, royalties from sale kits for AQP4 IgG detetction and from clinical service assays performed outside Mayo clinic. Dr. Leavitt has nothing to disclose. Dr Flanagan has nothing to disclose. Dr. Tobin has nothing to disclose. Dr. Lopez has nothing to disclose. Dr. Keegan has nothing to disclose. Dr. Lucchinetti has nothing to disclose. Dr. Kantarci has nothing to disclose. Dr. Sagen has nothing to disclose. Dr. Pittock has nothing to disclose. %U